At RSNA, Benedikt Schneider, co-founder and CEO of Floy, discusses how opportunistic screening and AI-assisted diagnostic tools are supporting earlier diagnosis, broader clinical insights, and growing adoption across European radiology practices.
Opportunistic screening represents a valuable approach to enabling earlier diagnosis and improving patient outcomes, with growing adoption across clinical practice. At RSNA 2025, Floy highlights its experience in this field, with more than 300 sites currently using its technologies across Europe. According to co-founder and CEO Benedikt Schneider, patients benefit directly when findings – such as osteoporosis detected from spinal CT or MRI scans – are identified opportunistically during routine imaging.
Beyond clinical value, Schneider points to the importance of clinical, operational, and economic considerations in driving adoption. Radiologists recognize the benefit of offering a broader diagnostic spectrum, while Floy also supports implementation models that allow findings to be offered as self-pay services. This creates a direct incentive for radiology practices while expanding the diagnostic information available to patients.
Floy’s portfolio spans both opportunistic screening and AI-assisted diagnosis, with a particular focus on volumetric assessment. These applications enable quantification of organs, subcutaneous and visceral fat, and liver steatosis from CT and MRI data, helping radiologists build a more comprehensive diagnostic picture. As imaging workloads continue to rise, such tools are designed to support faster and more accurate diagnosis without increasing imaging volume.
Looking ahead, Schneider sees artificial intelligence playing an increasingly central role in radiology. AI-supported, quantified assessments across specialties are expected to help radiologists extract broader insights from existing images, supporting precise diagnosis and better-informed clinical decision-making – ultimately benefiting both clinicians and patients.
